文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

降钙素原与C反应蛋白用于排除COVID-19重症患者早期细菌合并感染

Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients.
PubMed 文献 · Intensive Care Med · 2023-07-28
一句话结论多中心队列显示,入院单次PCT或CRP虽阴性预测值高,但AUC低,作者认为不足以单独排除或确认COVID-19重症患者的细菌合并感染。

该多中心观察性队列纳入55个西班牙ICU连续收治的4076例COVID-19患者,其中133例(3%)存在细菌合并感染。入院时PCT和CRP的ROC曲线下面积分别为0.57(95%CI 0.51-0.61)和0.6(95%CI 0.55-0.64),阴性预测值分别为97.5%(95%CI 96.5-98.5)和98.2%(95%CI 97.5-98.9)。CRP单独与细菌合并感染相关(OR 2,95%CI 1.25-3.19;p=0.004),PCT≥0.12 ng/mL与90天死亡率升高相关。作者认为单次PCT和CRP检测不能用于确认或排除COVID-19病毒性肺炎的细菌合并感染。

要点

  • 4076例COVID-19重症患者中仅133例(3%)存在细菌合并感染,入院时PCT和CRP的AUC分别仅0.57和0.6,判别能力低。
  • PCT与CRP的阴性预测值分别达97.5%(95%CI 96.5-98.5)和98.2%(95%CI 97.5-98.9),但作者仍认为单次检测不能用于排除细菌合并感染。
  • CRP单独与细菌合并感染相关(OR 2,95%CI 1.25-3.19;p=0.004)。
  • 细菌合并感染组15、30、90天总死亡率有升高趋势但无显著差异;PCT≥0.12 ng/mL与90天死亡率升高相关。

适用人群与场景

  • 2020年2月5日至2021年12月21日期间连续收入55个西班牙ICU的COVID-19肺炎患者,共4076例。

研究设计与关键结果

  • 研究类型为多中心观察性队列研究,纳入55个西班牙ICU连续收治的4076例COVID-19患者,其中133例(3%)存在细菌合并感染。
  • 主要终点为入院时PCT或CRP血清水平预测细菌合并感染:PCT的ROC曲线下面积0.57(95%CI 0.51-0.61),CRP为0.6(95%CI 0.55-0.64);阴性预测值PCT 97.5%(95%CI 96.5-98.5),CRP 98.2%(95%CI 97.5-98.9)。
  • CRP单独与细菌合并感染相关(OR 2,95%CI 1.25-3.19;p=0.004)。
  • 细菌合并感染组15、30、90天总死亡率有升高趋势但无显著差异;PCT≥0.12 ng/mL与90天死亡率升高相关。
  • 另在高风险特征人群中进行亚组分析。

证据类型、等级与局限

  • 证据类型:多中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,单次、单一时间点检测PCT和CRP不能用于确认或排除COVID-19病毒性肺炎患者的细菌合并感染。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Although the prevalence of community-acquired respiratory bacterial coinfection upon hospital admission in patients with coronavirus disease 2019 (COVID-19) has been reported to be < 5%, almost three-quarters of patients received antibiotics. We aim to investigate whether procalcitonin (PCT) or C-reactive protein (CRP) upon admission could be helpful biomarkers to identify bacterial coinfection among patients with COVID-19 pneumonia.

METHODS: We carried out a multicentre, observational cohort study including consecutive COVID-19 patients admitted to 55 Spanish intensive care units (ICUs). The primary outcome was to explore whether PCT or CRP serum levels upon hospital admission could predict bacterial coinfection among patients with COVID-19 pneumonia. The secondary outcome was the evaluation of their association with mortality. We also conducted subgroups analyses in higher risk profile populations.

RESULTS: Between 5 February 2020 and 21 December 2021, 4076 patients were included, 133 (3%) of whom presented bacterial coinfection. PCT and CRP had low area under curve (AUC) scores at the receiver operating characteristic (ROC) curve analysis [0.57 (95% confidence interval (CI) 0.51-0.61) and 0.6 (95% CI, 0.55-0.64), respectively], but high negative predictive values (NPV) [97.5% (95% CI 96.5-98.5) and 98.2% (95% CI 97.5-98.9) for PCT and CRP, respectively]. CRP alone was associated with bacterial coinfection (OR 2, 95% CI 1.25-3.19; p = 0.004). The overall 15, 30 and 90 days mortality had a higher trend in the bacterial coinfection group, but without significant difference. PCT ≥ 0.12 ng/mL was associated with higher 90 days mortality.

CONCLUSION: Our study suggests that measurements of PCT and CRP, alone and at a single time point, are not useful for ruling in or out bacterial coinfection in viral pneumonia by COVID-19.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Galli F, Bindo F, Motos A, et al. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients. Intensive Care Med. 2023. PMID: 37507573. doi:10.1007/s00134-023-07161-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。